| Name | Title | Contact Details |
|---|
Feinstein Kean Healthcare is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Cambridge, MA. To find more information about Feinstein Kean Healthcare, please visit www.fkhealth.com
Express Scripts (NASDAQ: ESRX) manages more than a billion prescriptions each year for tens of millions of patients. On behalf of our clients – employers, health plans, unions and government health programs – we make the use of prescription drugs safer and more affordable. Express Scripts uniquely combines three capabilities – behavioral sciences, clinical specialization and actionable data – to create Health Decision Science℠, our innovative approach to help individuals make the best drug choices, pharmacy choices and health choices. Better decisions mean healthier outcomes. Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.
Diagnostic Centers of America is a Delray Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Middle Peninsula Northern Neck Community Services Board is a public, nonprofit organization providing services to meet the needs of individuals and their families who have problems associated with mental health, intellectual disabilities, substance abuse, and developmental disabilities. Services are provided to residents in the Middle Peninsula and Northern Neck, VA. This area includes the counties of Westmoreland, Richmond, Essex, Northumberland, Lancaster, Gloucester, Mathews, Middlesex King & Queen and King William. It also includes the Town of Colonial Beach and West Point.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.